US2006293261A1PendingUtilityA1

Clarithromycin or a salt thereof for the treatment or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli

Assignee: TAISHO PHARMACEUTICAL CO LTDPriority: Jun 24, 2005Filed: Jun 24, 2005Published: Dec 28, 2006
Est. expiryJun 24, 2025(expired)· nominal 20-yr term from priority
A61P 43/00A61K 31/7048A61P 11/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.

Claims

exact text as granted — not AI-modified
1 . A method for treating or preventing a pulmonary disorder caused by the destruction of pulmonary alveoli in a mammal in need of such treatment or prevention, the method comprising administering to the mammal, an effective amount of clarithromycin or a salt thereof.  
   
   
       2 . The method according to  claim 1 , wherein the pulmonary disorder is pulmonary emphysema or a pulmonary emphysema condition.  
   
   
       3 . The method according to  claim 2 , wherein the pulmonary emphysema condition is chronic obstructive pulmonary disease.  
   
   
       4 . A pharmaceutical composition for the treatment or prevention of a pulmonary disorder caused by the destruction of pulmonary alveoli comprising an effective amount of clarithromycin or a salt thereof and a pharmaceutically acceptable carrier.  
   
   
       5 . The pharmaceutical composition according to  claim 4 , wherein the pulmonary disorder is pulmonary emphysema or a pulmonary emphysema condition.  
   
   
       6 . The pharmaceutical composition according to  claim 5 , wherein the pulmonary emphysema condition is chronic obstructive pulmonary disease.  
   
   
       7 . A therapeutic or prophylactic agent for a pulmonary disorder caused by the destruction of pulmonary alveoli comprising as an effective ingredient, clarithromycin or a salt thereof.  
   
   
       8 . The use of clarithromycin or a salt thereof in the manufacture of a medicament for the treatment or prevention of a pulmonary disorder caused by the destruction of pulmonary alveoli.

Join the waitlist — get patent alerts

Track US2006293261A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.